A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer-Reference-Cited by-同舟云学术

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

Published:2020-10 Issue:2 Volume:183 Page:347-362.e24
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Ott Patrick A.^ORCID,Hu-Lieskovan Siwen,Chmielowski Bartosz^ORCID,Govindan Ramaswamy,Naing Aung,Bhardwaj Nina,Margolin Kim,Awad Mark M.^ORCID,Hellmann Matthew D.^ORCID,Lin Jessica J.^ORCID,Friedlander Terence^ORCID,Bushway Meghan E.,Balogh Kristen N.,Sciuto Tracey E.^ORCID,Kohler Victoria,Turnbull Samantha J.^ORCID,Besada Rana^ORCID,Curran Riley R.,Trapp Benjamin,Scherer Julian,Poran Asaf^ORCID,Harjanto Dewi^ORCID,Barthelme Dominik,Ting Ying Sonia,Dong Jesse Z.,Ware Yvonne,Huang Yuting,Huang Zhengping^ORCID,Wanamaker Amy,Cleary Lisa D.,Moles Melissa A.,Manson Kelledy,Greshock Joel^ORCID,Khondker Zakaria S.,Fritsch Ed^ORCID,Rooney Michael S.,DeMario Mark^ORCID,Gaynor Richard B.,Srinivasan Lakshmi^ORCID

Funder

Neon Therapeutics/BioNTech US

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference79 articles.

1. Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction;Abelin;Immunity,2017

2. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction;Abelin;Immunity,2019

3. MHC-II neoantigens shape tumour immunity and response to immunotherapy;Alspach;Nature,2019

4. ea-utils: “Command-line tools for processing biological sequencing data;Aronesty,2011

5. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade;Ayers;J. Clin. Invest.,2017

Cited by 418 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics;Current Pharmaceutical Biotechnology;2024-12

2. Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy;International Immunopharmacology;2024-12

3. A recent perspective on designing tumor vaccines for tumor immunology;International Immunopharmacology;2024-12

4. Advances in Vaccines for Melanoma;Hematology/Oncology Clinics of North America;2024-10

5. Firing up “cold” tumors: Ferroptosis causes immune activation by improving T cell infiltration;Biomedicine & Pharmacotherapy;2024-10